echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > The gut bacteria "mess up", and the spinal cord may also suffer!

    The gut bacteria "mess up", and the spinal cord may also suffer!

    • Last Update: 2023-02-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    *For medical professionals
    only



    In treatment-naïve cases, bacterial abundance was positively correlated
    with disease activity.



    Executive Summary


    On January 5, 2023, a study published in the journal Genomic Medicine found that there are considerable aberrations in the gut microbiota of patients with multiple sclerosis, directly related to blood biomarkers of inflammation, and in treatment-naïve cases, bacterial richness is positively correlated
    with disease activity.


    Study screenshots

    status quo


    Multiple sclerosis is a chronic, immune-mediated brain and spinal cord disorder that causes physical and cognitive impairment
    in young people.
    It is hypothesized that the disrupted bacterial and viral gut microbiota is part of the pathogenesis of
    disease-mediated disease effects through altered gut microbiota-brain axis.

    Professor Finn Sellebjerg, clinical professor at Rigshospitalet and the University of Copenhagen and one of the researchers, said:
    • Some bacterial groups occur more frequently in people with multiple sclerosis, while others are more common in people without multiple sclerosis;
    • We also saw that receiving multiple sclerosis treatment appeared to be associated with
      changes in bacterial composition compared to patients who did not receive treatment.

    conclusion


    The study included 148 Danish multiple sclerosis patients and an equal number of healthy control subjects who provided blood and stool samples
    at the start of the study and again two years later.
    Using genetic analysis, researchers can determine which bacteria are in the gut and what effects these bacteria have
    .

    When all multiple sclerosis cases were compared to healthy controls, the study found:
    • There were varying abundances of 61 bacterial species, of which 31 were enriched in cases;
    • Inflammatory marker clusters consisting of blood leukocytes, CRP, and blood cell gene expression of IL17A and IL6 were positively correlated with multiple sclerosis-associated species clusters;
    • In cases of treatment-naïve multiple sclerosis with active treatment of the disease, a richer bacterial species was positively correlated with a group of plasma cytokines including IL-22, IL-17A, IFN-β, IL-33 and TNF-α;
    • The richness of bacterial species in treatment-naïve multiple sclerosis cases was related to the number of relapses at 2 years of follow-up;
    • In addition, multiple sclerosis cases have high virus species diversity and high phage abundance
      .

    prospect


    Professor Oluf Borbye Pedersen of the University of Copenhagen said:

    • Perhaps the most interesting aspect of the study is that we found specific gut bacteria that produce certain fatty acids that we can't form on our own, as well as a substance called urolithin;
    • If these observations can be confirmed in independent studies, the next step would be to initiate therapeutic trials such as cocktails of anti-inflammatory, green diets and next-generation probiotics that also modulate immunity but are not yet on the market;
    • Unfortunately, there is still some way to go
      before we can provide specific advice on lifestyle or bacterial supplements that enhance health.

    Sellebjerg added:

    • We can't do anything about some of these things, for example, we can't get rid of the Epstein-Barr virus, we can't change genetics, etc.
      , but we can quit smoking and take vitamin D supplements, although these are not strong risk factors;
    • However, we are now beginning to identify some bacterial strains with beneficial effects;
    • Perhaps in the long term, the patient will be able to take dietary supplements that promote the development of the right gut bacteria, or we can take gut bacteria
      that promote good metabolism of the gut.
    • Our results give us a few more pieces of the 10,000-piece puzzle in multiple sclerosis, but there is still a big gap;
    • The big difference is that the debris we find is beginning to reveal systems that we can manipulate without the side effects
      that some drugs can have.


    Click "Read Original" to get more clinical dry goods

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.